Patel, G;
Prince, A;
Harries, M;
(2024)
Advanced Triple-Negative Breast Cancer.
Seminars in Oncology Nursing
, 40
(1)
, Article 151548. 10.1016/j.soncn.2023.151548.
![[thumbnail of SONU-D-23-00183_R1_redacted.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
SONU-D-23-00183_R1_redacted.pdf - Accepted Version Access restricted to UCL open access staff until 9 February 2025. Download (1MB) |
Abstract
OBJECTIVE: Our focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide. DATA SOURCES: Peer-reviewed literature, clinical practice guidelines, clinical trial, and government websites. CONCLUSION: Triple-negative breast cancer is a highly heterogeneous subtype of breast cancer, often associated with a less favorable prognosis compared to other types. Significant advances in our understanding of specific mutations and signaling pathways within this subtype, coupled with expanding therapeutic options, has broadened the treatment landscape considerably. While chemotherapy traditionally formed the mainstay of treatment, new therapeutics such as immunotherapy, targeted agents, and antibody-drug conjugates in first-line and subsequent-line settings are now available. It is essential for all those who care for this patient group to be up-to-date on current practice and emerging treatments, so patients receive the support they need and deserve. IMPLICATIONS FOR NURSING PRACTISE: Nurses need to become familiar with new systemic anticancer therapies within advanced triple-negative breast cancer to provide patients with adequate information about new treatment options and support with potential treatment-associated toxicities. It is important for nurses to be able to recognise key issues facing patients with a diagnosis of advanced triple-negative breast cancer, to gain a deeper understanding of both the physical and psychosocial support required, signposting or referring patients to additional support services if needed.
| Type: | Article |
|---|---|
| Title: | Advanced Triple-Negative Breast Cancer |
| Location: | United States |
| DOI: | 10.1016/j.soncn.2023.151548 |
| Publisher version: | http://dx.doi.org/10.1016/j.soncn.2023.151548 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | Antibody–drug conjugate, Immunotherapy, Specialist nurse, Targeted therapy, Triple-negative breast cancer |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10193998 |
Archive Staff Only
 |
View Item |
